Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Researchers aim to exploit DNA mutations in the treatment of blood and bone marrow cancers

In a clinical trial led by Yale Cancer Center and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer.

10 Dec 2019

Transplant patient finds out his DNA has been replaced by that of his donor

A bone marrow transplant recipient later found out that the DNA in his blood and semen had been replaced by that of his donor.

10 Dec 2019

Rutgers researchers identify small mutations for AML and MDS through deep DNA sequencing

Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations.

9 Dec 2019

Pairing chemotherapy azacitidine with enasidenib boosts complete remission in AML patients

A multi-institutional, Phase II study led by The University of Texas MD Anderson Cancer Center showed that pairing standard chemotherapy azacitidine (AZA) with a drug called enasidenib (ENA) measurably boosts complete remission in patients newly diagnosed with a specific form of acute myeloid leukemia (AML).

9 Dec 2019

Yale study highlights the need to develop effective, less toxic approaches to treat AML patients

A new study by Yale Cancer Center researchers shows understanding treatment patterns for patients with acute myeloid leukemia is vital to develop strategies to improve outcomes.

9 Dec 2019

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

8 Dec 2019

Genetic features of AML in older patients can predict outcomes after stem cell transplant

For older patients with acute myeloid leukemia, the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the 61st American Society of Hematology (ASH) Annual Meeting.

8 Dec 2019

Scientists develop new therapy for acute myeloid leukemia

Cold Spring Harbor Laboratory scientists, with chemists and cancer biologists from Dana-Farber Cancer Institute, have developed a new therapy that extended the survival of mice with acute myeloid leukemia.

19 Nov 2019

New AI-driven approach for single blood cell classification

For the first time, researchers from Helmholtz Zentrum München and the University Hospital of LMU Munich show that deep learning algorithms perform similar to human experts when classifying blood samples from patients suffering from acute myeloid leukemia.

12 Nov 2019

Fujitsu successfully verifies AI technology to improve efficiency in cancer genomic medicine

Fujitsu has announced the results of a joint research project it has been conducting with the Institute of Medical Science at the University of Tokyo since April 2018.

6 Nov 2019

New guide for genomic diagnosis of myelodysplastic syndromes and chronic myelomonocytic leukemia published

In Spain, a workgroup of more than 400 researchers, the Spanish Group of Myelodysplastic Syndromes, meets twice a year to present projects and undertake collaborations that improve their work in the fight against Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, two types of blood cancers.

4 Nov 2019

Avocados may hold the key to managing obesity and preventing diabetes

Your guacamole may hold the key to managing obesity and helping delay or prevent diabetes, according to a new study by a University of Guelph research team.

30 Oct 2019

University Of Minnesota opens clinical trial of first-of-its-kind NK cell cancer immunotherapy

A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia and B-cell lymphoma.

21 Oct 2019

Combination of two drugs disrupts cancer cells' ability to survive DNA damage, study finds

In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine have identified a new pathway that leads to the destruction of cancer cells.

14 Oct 2019

Targeting two genetic faults in cancer cells could hold the key to treating leukemia

Faults in two genes directly work together to bring about the deadliest form of blood cancer, scientists have discovered in a study that could pave the way for better treatments.

4 Oct 2019

Researchers discover metabolic vulnerability in cancer cells with mutated spliceosomes

A research team from the Johns Hopkins Kimmel Cancer Center reports it has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes.

From Johns Hopkins Medicine 3 Oct 2019

Two cell mutations contribute to the development of acute myeloid leukemia

Sometimes the whole is greater than the sum of its parts. Researchers at Cold Spring Harbor Laboratory have discovered that two cell mutations, already harmful alone, enhance one another's effects, contributing to the development of the deadly blood cancer acute myeloid leukemia (AML).

3 Oct 2019

Acute Myeloid Leukemia News and Research

Further Reading

Researchers aim to exploit DNA mutations in the treatment of blood and bone marrow cancers

Transplant patient finds out his DNA has been replaced by that of his donor

Rutgers researchers identify small mutations for AML and MDS through deep DNA sequencing

Pairing chemotherapy azacitidine with enasidenib boosts complete remission in AML patients

Yale study highlights the need to develop effective, less toxic approaches to treat AML patients

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

Genetic features of AML in older patients can predict outcomes after stem cell transplant

Scientists develop new therapy for acute myeloid leukemia

New AI-driven approach for single blood cell classification

Fujitsu successfully verifies AI technology to improve efficiency in cancer genomic medicine

New guide for genomic diagnosis of myelodysplastic syndromes and chronic myelomonocytic leukemia published

Avocados may hold the key to managing obesity and preventing diabetes

University Of Minnesota opens clinical trial of first-of-its-kind NK cell cancer immunotherapy

Combination of two drugs disrupts cancer cells' ability to survive DNA damage, study finds

Targeting two genetic faults in cancer cells could hold the key to treating leukemia

Researchers discover metabolic vulnerability in cancer cells with mutated spliceosomes

Two cell mutations contribute to the development of acute myeloid leukemia

Study reveals molecular mechanism of cancer malignancy and development of leukemia

Newly synthesized anticancer compound can block cancer signaling mechanism

Discovery of combination protein leads to first-in-human clinical trial for leukemia

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News